The New Peptide Policy Is Narrower Than a “Green Light”

The New Peptide Policy Is Narrower Than a “Green Light”

An October 30 federal notice names six peptide substances for conditional compounding enforcement discretion. It does not approve those drugs or settle every access question.

Did HHS give every peptide a green light? The October 30 Federal Register notice says something narrower. It announces an interim policy for certain substances used by qualifying compounders under specific circumstances while the federal 503A bulk-substances list is developed through rulemaking. The current HHS policy document names six peptides in Appendix A. That list is a starting point, not a drug-approval certificate.

The distinction matters because “peptides” is a category, not one product with one evidence base or legal status. A reader who hears that a peptide was “cleared” needs to ask: Which substance? Which form and route? Which compounder and patient? And cleared for what action?

What the document actually lists

Appendix A names BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. It does not name retatrutide. That absence is a useful check on a blanket claim, but it does not by itself answer every question about retatrutide's trial access, prescribing, importation, possession or other jurisdictions. Those are different questions with different authorities.

The HHS document goes beyond names. Appendix B specifies identities and route limitations for the listed substances. The interim stance concerns a particular federal compounding pathway, section 503A of the Food, Drug, and Cosmetic Act. HHS says that, while the list is developed through rulemaking, it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding a product with an Appendix A substance when all specified circumstances are present. This is HHS's stated policy, not an independent finding that any particular product is safe, effective or lawful in every setting.

The “if” behind the announcement

The policy sets out ten numbered circumstances. Among them, the bulk substance must appear in Appendix A and match the identity and route limitations in Appendix B. The source and certificate of analysis must meet characterization requirements. The policy addresses registered manufacturing, quality documentation, reporting of serious adverse events and product-quality problems, labeling, a single Appendix A active ingredient, certain route and device restrictions, and compliance with other applicable requirements. It also refers to section 503A's patient-specific prescription requirement. The HHS text provides the full conditions; this summary is not a checklist for qualifying a real pharmacy or prescription.

Consider the difference between two claims. “BPC-157 appears on Appendix A” is a source-checkable statement about the current policy. “Any BPC-157 product is now approved and safe to buy” does not follow. The first identifies one item on a list. The second skips the conditions, the product's actual identity and quality, the patient-specific setting, and the difference between enforcement discretion and approval.

Enforcement discretion is not FDA approval

The Federal Register notice and HHS policy both state that compounded drugs are not FDA-approved; FDA has not reviewed their safety, effectiveness or quality before marketing in the way it reviews approved drugs. An enforcement policy says how an agency currently intends to act in a defined circumstance. It does not produce a clinical trial result, establish an individual treatment benefit or erase product-quality risks.

HHS describes this as an interim policy while the 503A bulk-substances list is developed. The notice calls the policy draft and nonbinding, and HHS says it may revisit it if safety or quality concerns arise. Publication on October 30 makes the notice available; it does not mean the later rulemaking has already ended. The HHS website is identified in the notice as the place to find the current policy version, so a time-sensitive summary should be checked again before relying on it.

A better way to read the next claim

The useful question is not “Are peptides approved now?” It is: What exact substance and form does the current document address, under which conditions, and what conclusion does the source actually support? A policy page can answer the first part. It cannot replace clinical evidence for efficacy, a regulator's product-approval record, or professional advice about an individual situation.

This article is an evidence guide, not medical or legal advice. It does not recommend acquiring, compounding or using any peptide. If a product or treatment is relevant to a personal decision, ask an appropriately qualified clinician and verify current regulator information for the relevant jurisdiction.

Sources and date: Federal Register notice 2026-22192, published October 30, 2026; HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, including Appendices A and B. Checked October 30, 2026.